by The Welthi Bureau | 28 JULY 2018
Mumbai, Baltimore, 27th July 2018: Pharma major Lupin announced the launch of its Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Desoximetasone Topical Spray, 0.25% is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.’s Topicort® Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
Desoximetasone Topical Spray, 0.25% had annual sales of approximately USD 18.7 million in the US (IQVIA MAT May 2018).
Cryotherapy pain treatment Advanced Physio ...
Suma Neuro Care should be at the forefront of ...
Patients with Liver ailments too can opt for ...
Wockhardt Hospitals, Mira Road Successfully ...
Big relief for a 15 year old boy from severe ...
KIMS doctors salvaged the limb of a farmer with ...
Wockhardt Hospital, Mira Road conducts free ...
SuVitas Launches Bangalore’s First Dedicated ...
Healthcare receives major limelight in General ...